Aselizumab, designated HuDreg-55, signifies a emerging therapeutic agent developed to bind to complement protein . Its mode of action involves interfering with the traditional complement pathway, https://hudreg-55127325.blog-gold.com/279205/aselizumab-a-in-depth-exploration-into-hudreg-55